C.R. Bard vs. AngioDynamics: Settlement Resolves Implantable Port Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | C.R. Bard, Inc. v. AngioDynamics, Inc. |
| Case Number | 1:20-cv-01544 (D. Del.) |
| Court | District of Delaware |
| Duration | Nov 17, 2020 – Apr 8, 2024 ~3.4 years |
| Outcome | Settlement — Confidential Terms |
| Patents at Issue | |
| Accused Products | AngioDynamics’s Power Injectable Implantable Port Systems, Smart Port product line |
Case Overview
A multi-year patent infringement battle over power-injectable implantable port technology concluded in April 2024 when C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. reached a confidential settlement with AngioDynamics, Inc., resulting in a stipulated dismissal with prejudice in the Delaware District Court. Filed in November 2020, Case No. 1:20-cv-01544 centered on three U.S. patents covering implantable vascular access port technology — a high-stakes segment of the interventional medical device market.
For patent attorneys, IP professionals, and R&D leaders operating in the medical device space, this case reflects a recurring strategic pattern: aggressive assertion of foundational device patents by market incumbents against competitors offering functionally similar products. The settlement, while terms remain undisclosed, preserves both parties’ reputations while avoiding the unpredictability of trial. Understanding the procedural arc and strategic dynamics of this dispute offers actionable intelligence for anyone navigating implantable port patent litigation or adjacent medical device IP conflicts.
The Parties
⚖️ Plaintiff
Established leader in vascular access and peripheral intervention technology, holding a substantial IP portfolio in implantable port systems.
🛡️ Defendant
Publicly traded medical device company specializing in vascular access, oncology, and surgical solutions with its Smart Port line.
The Patents at Issue
This landmark case involved three utility patents covering power-injectable implantable port systems engineered to withstand high-pressure injection rates for contrast media delivery during CT imaging. These patents define a clinically significant capability differentiating them from conventional venous access devices.
- • U.S. Patent No. 7,959,615 B2 (Application No. 12/023,280)
- • U.S. Patent No. 7,785,302 B2 (Application No. 11/368,954)
- • U.S. Patent No. 7,947,022 B2 (Application No. 12/420,028)
Designing a new implantable port?
Check if your medical device design might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case concluded via stipulated dismissal with prejudice pursuant to Federal Rule of Civil Procedure 41, executed on April 8, 2024. The dismissal reflects a negotiated settlement agreement, the specific financial terms of which were not publicly disclosed. Critically:
- • All claims and counterclaims were dismissed with prejudice
- • Each party bears its own costs, expenses, and attorney’s fees
- • Both parties expressly waived any right to seek attorney’s fees under 35 U.S.C. § 285
- • The court retained jurisdiction to enforce the dismissal order
- • All pending motions were rendered moot upon settlement
The mutual fee waiver under § 285 is a notable provision. By explicitly disclaiming fee recovery, both parties signaled a desire for a clean resolution without lingering litigation risk — a common feature of settlements where neither side achieved a decisive legal advantage prior to resolution.
Key Legal Issues
The case was filed as a straightforward patent infringement action. In multi-patent medical device disputes of this type, defendants typically pursue a parallel strategy combining: (1) invalidity challenges based on prior art, obviousness, or lack of enablement; (2) non-infringement arguments grounded in claim construction; and (3) inter partes review (IPR) petitions at the USPTO as a cost-effective validity challenge mechanism. The deployment of three separate defense firms suggests AngioDynamics mounted a comprehensive, multi-front defense.
No specific claim construction rulings, expert testimony, or dispositive motion outcomes were disclosed in the available case record. The settlement prior to trial means no judicial findings on validity or infringement were rendered.
Freedom to Operate (FTO) Analysis in Medical Devices
This case highlights critical IP risks in the vascular access device market. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation in the medical device sector.
- View Bard’s extensive patent portfolio
- Analyze active players in vascular access technology
- Understand competitive IP enforcement patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own implantable port technology or product.
- Input your device description or technical features
- AI identifies potentially blocking utility patents
- Get actionable risk assessment report for medical devices
High Risk Area
Power-injectable port technology
3 Patents at Issue
Covering critical device features
FTO Analysis
Essential for market entry
✅ Key Takeaways
Stipulated dismissal with bilateral § 285 fee waivers signals a pragmatic, risk-balanced settlement — neither party conceded liability.
Search related case law →Multi-patent assertion in Delaware remains a potent enforcement strategy for medical device IP holders.
Explore precedents →Defense coalition structures (multiple firms, specialized roles) are standard in high-stakes medical device patent cases.
Monitor Bard/BD’s active patent portfolio for continuation filings extending coverage of power-injectable port technology.
Track patent families →Evaluate whether settlement terms in comparable cases include licensing provisions that reshape competitive dynamics.
Case duration (~3.4 years) should inform litigation budget planning for multi-patent medical device disputes.
Frequently Asked Questions
Bard asserted U.S. Patent Nos. 7,959,615 B2, 7,785,302 B2, and 7,947,022 B2 — all covering power-injectable implantable port technology used in high-pressure contrast media delivery.
The parties entered a confidential settlement agreement and jointly stipulated to dismissal under Fed. R. Civ. P. 41, with each side bearing its own costs and waiving fee recovery under 35 U.S.C. § 285.
It reinforces that multi-patent assertions in Delaware by established medical device companies retain strong settlement leverage, and that FTO analysis covering foundational vascular access IP is essential for market entrants.
Companies can protect themselves by conducting freedom-to-operate (FTO) analysis before finalising product aesthetics, documenting design evolution thoroughly, considering design-around strategies for high-risk design elements, and filing their own design patents early in the product development cycle. PatSnap Eureka’s FTO tools help R&D and IP teams identify potentially blocking design patents before products go to market.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Center – Search Patent Nos. 7,959,615 / 7,785,302 / 7,947,022
- PACER Case Locator – Case 1:20-cv-01544
- Delaware District Court IP Docket
- Cornell Legal Information Institute — 35 U.S.C. § 285
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.